**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 60047

**Manuscript Type:** CASE REPORT

**Vancomycin-induced thrombocytopenia in endocarditis: A case report and** **review of literature**

Guleng SR *et al*. Vancomycin-induced thrombocytopenia in endocarditis

Si-Ri Guleng, Ri-Han Wu, Xiao-Bin Guo

**Si-Ri Guleng, Ri-Han Wu, Xiao-Bin Guo,** Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010010, Inner Mongolia Autonomous, China

**Author contributions:** Guleng SR and Wu RH collected the case information and drafted the manuscript; Guleng SR and Guo XB analyzed the data and revised the manuscript; all authors issued the final approval for the version to be submitted.

**Supported by** the Inner Mongolia Autonomous Region People's Hospital Training Talent Research Start-up Fund, No. BS201703.

**Corresponding author: Si-Ri Guleng, PhD, Chief Doctor,** Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, No. 20 Zhaowuda Road, Saihan District, Hohhot 010010, Inner Mongolia Autonomous, China. srgl985@126.com

**Received:** October 13, 2020

**Revised:** December 28, 2020

**Accepted:** January 22, 2021

**Published online:**

**Abstract**

BACKGROUND

Thrombocytopenia is a serious complication in the medical practice of numerous drugs. Vancomycin is frequently used for the prophylaxis and treatment of suspected or identified methicillin-resistant positive infections. Several cases with vancomycin-induced thrombocytopenia (VIT) have been reported. However, these have rarely been extensively reviewed. The present report describes a case of VIT in endocarditis, and reviews all VIT cases reported in the literature.

CASE SUMMARY

A 26-year-old male diagnosed with infective endocarditis was admitted. The patient was treated with multiple drugs, including vancomycin, which was initially intravenously given at 1000 mg every 12 h and subsequently at 500 mg every 8 h on day 3. On day 11, the platelet count decreased to 51 × 109/L, vancomycin was switched to 500 mg every 12 h, and platelet transfusion was given. On day 17, the platelet count dropped to 27 × 109/L, and platelet transfusion was administered again. On day 23, vancomycin was adjusted to 500 mg every 8 h as the trough concentration dropped to the minimum effective concentration. On day 33, the platelet count declined to approximately 40 × 109/L. After platelet transfusion, the platelet count rebounded to 90 × 109/L on day 35 but dropped again to 42 × 109/L on day 43. Based on the time-to-platelet count curve and Naranjo’s Adverse Drug Reaction Probability Scale score, VIT was suspected. After vancomycin discontinuation and platelet transfusion, the platelet count gradually normalized.

CONCLUSION

The diagnosis of VIT can be achieved through the time-to-platelet count curve and Naranjo’s Adverse Drug Reaction Probability Scale score. The platelet count cannot be normalized simply by platelet transfusion alone, and vancomycin discontinuation is essential.

**Key Words:** Case report; Vancomycin; Thrombocytopenia; Endocarditis; Platelet transfusion; Literature review

Guleng SR, Wu RH, Guo XB. Vancomycin-induced thrombocytopenia in endocarditis: A case report and review of literature. *World J Clin Cases* 2021; In press

**Core Tip:** The present report describes a case of vancomycin-induced thrombocytopenia (VIT) in endocarditis and reviews all VIT cases reported in the literature, in terms of indications, diagnosis, management, and potential molecular mechanisms. The present case highlights the importance of accurate diagnosis of VIT in endocarditis, which can be achieved through the time-to-platelet count curve and the Naranjo’s Adverse Drug Reaction Probability Scale score. The platelet count cannot be normalized simply by platelet transfusion alone, and the discontinuation of vancomycin is essential. Due to the anamnestic response to vancomycin re-exposure and the formation of vancomycin-dependent antiplatelet antibodies, the re-administration of vancomycin should be avoided.

**INTRODUCTION**

Thrombocytopenia, which is generally defined as a platelet count of less than 100 × 109/L of blood or a decrease in the platelet count of 20%-50% from baseline[1,2], has been considered as an adverse reaction correlated to drugs used in the treatment of various diseases[3]. Drug-induced thrombocytopenia is mostly caused by immune-mediated platelet degradation and is always drug dependent, indicating that the platelet count can return to baseline levels after the discontinuation of medications[4]. Although it has been reported that approximately 10 million persons per year are suspected to suffer from drug-induced thrombocytopenia[5], its incidence has not been well-defined[4].

Antibiotic-induced thrombocytopenia has been documented[3]. The commonly reported antibiotics that induce thrombocytopenia are β-lactam antibiotics agents (such as penicillin, nafcillin, ticarcillin, cefazolin, cefuroxime, ceftriaxone, and piperacillin) and linezolid[6]. Vancomycin is a first-generation glycopeptide antibiotic that is often used for the prophylaxis and treatment of suspected or identified methicillin-resistant infections, such as *Staphylococcus aureus* infection[7], and has been considered as an uncommon cause of thrombocytopenia[6]. Several clinical observational studies have suggested that the incidence of vancomycin-induced thrombocytopenia (VIT) might be higher than that induced by linezolid[1]. However, the incidence of VIT may have been overestimated, because the definition for thrombocytopenia used among these studies vary. A platelet count of less than 150 × 109/L was used in two studies[8,9], and a decrease in platelet count of at least 50% from baseline was used in another study[1]. In addition, the clinical manifestations, diagnosis, and management of VIT have not been well-established, and the underlying molecular mechanisms by which vancomycin induces thrombocytopenia needs to be further elucidated[10]. Over the past two decades, cases with VIT have been continuously reported[11]. However, these cases have rarely been extensively reviewed.

In June 2019, a young male patient with endocarditis was admitted to our hospital, and he developed VIT after vancomycin therapy during the treatment for endocarditis. The present report describes this case and extensively reviews all VIT cases reported in the literature, in terms of indications, diagnosis, management, and potential molecular mechanisms.

**CASE PRESENTATION**

***Chief complaints***

A 26-year-old Chinese male presented with dyspnea, fatigue, arrhythmias, fever, and cough.

***History of present illness***

The patient was admitted to the hospital on June 6, 2019 and diagnosed with infective endocarditis, heart failure, and ventricular septal defect, with a series of manifestations of inflammatory response syndrome.

***History of past illness***

He had a medical history of uncontrolled hypotension and rheumatic heart disease.

***Personal and family history***

He denied any family history.

***Physical examination***

He had a body temperature of 39.1 °C and a heart rate of 100 beats per min.

***Laboratory examinations***

Initial laboratory testing showed no abnormality.

***Imaging examinations***

The electrocardiosignal data revealed a high echo of the tricuspid valve, suggesting a neoplasm.

**FINAL DIAGNOSIS**

Infective endocarditis, heart failure, and ventricular septal defect.

**TREATMENT**

During hospitalization, the patient was treated with multiple courses of drug therapy, which included vancomycin, omeprazole (40 mg q.d. for 10 d), ceftazidime (2 g t.i.d. for 9 d) and metoprolol (50 mg q.d. for 11 d). Based on the bacterial culture and drug susceptibility test, methicillin-resistant *Staphylococcus aureus* was identified with the minimum inhibitory concentration of less than 2 mg/L. Therefore, according to The Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infections in Adults and Children[12], vancomycin was prescribed for the patient with infective endocarditis. Initially, the patient was intravenously treated with 1000 mg of vancomycin every 12 h and 960 mg of benzylpenicillin every 8 h on day 2 for suspected gram-positive infections. The blood cultures were negative for two consecutive tests. Then, the intravenous administration of vancomycin was changed to 500 mg for every 8 h on day 3, for a trough concentration of 25.87 µg/mL beyond the upper limit of 20 µg/mL, and the platelet count was maintained within 100-110 × 109/L for 7 d. On day 11, the administration of vancomycin was switched to 500 mg every 12 h, because the platelet count decreased to 51 × 109/L and the peak concentration of vancomycin reached 57.2 µg/mL. Platelet transfusion (1 U) was given on day 11, and the platelet count slightly increased to 64 × 109/L on day 14, but dramatically dropped afterwards to 27 × 109/L on day 17. Then, platelet transfusion (1 U) was given again on day 17, and the platelet count steadily increased up to 67 × 109/L on day 31. The dose of vancomycin was adjusted to 500 mg every 8 h on day 23 when the trough concentration of vancomycin dropped to 8.86 µg/mL in order to ensure the minimal effective treatment concentration (10 µg/mL). However, on day 33, the hemoglobin level sharply dropped from 101 g/L to 54 g/L, the platelet count continuously declined to approximately 40 × 109/L, and platelet transfusion (1 U) was given. The platelet count rebounded to 90 × 109/L on day 35 but dropped to 42 × 109/L again on day 43. Based on these above observations, and along with the time-to-platelet count curve that illustrated the decline in platelet level after the administration of vancomycin (Figure 1), VIT was suspected, vancomycin was discontinued and replaced with daptomycin, and platelet transfusion (1 U) was given on the same day. The platelet count level increased and reached up to 120 × 109/L on day 50 and remained stable thereafter.

The concurrent antibiotic, benzylpenicillin, was continuously used during the period with little effect on the platelet count. The respiratory rate, white blood cell count, and hemodynamic variables remained stable, and the microbiological cultures from the sputum and urine revealed negative results, implying that no infection was correlated with thrombocytopenia for the present patient. The other causes of thrombocytopenia, including thrombotic thrombocytopenic purpura, hemolytic anemia, disseminated intravascular coagulation, and platelet-clumping pseudothrombocytopenia, were also excluded, because the results of the blood smear, bilirubin, and hemoglobin were normal. There have been no reports on the occurrence of drug-induced thrombocytopenia caused by other medications during treatment, including omeprazole, ceftazidime, and metoprolol. Therefore, a diagnosis of VIT was initially established using the time-to-platelet count curve. In addition, the Naranjo’s Adverse Drug Reaction Probability Scale score (Naranjo score) for vancomycin was 8, indicating the probable correlation between thrombocytopenia and vancomycin.

**OUTCOME AND FOLLOW-UP**

The patient was discharged from the hospital.

**DISCUSSION**

A literature search for all case reports on VIT published in English from April 1985 to June 2020 was performed on PMC/PubMed, Scopus, and Web of Science. Keywords, which included vancomycin and thrombocytopenia, were used to search the titles and abstracts. References of relevant case reports, according to the brief research, were also carefully checked. The demographic data (*e.g.,* age and gender), platelet count, diagnosis, and treatment were recorded and analyzed.

A total of 36 articles that reported 37 cases with VIT were identified in the literature. Thus, the data of 38 cases, which included the case described in the present report, were reviewed and are summarized in Table 1. Among these cases, 14 cases were females and 24 cases were males. The mean age of these cases was 51.19 ± 26.98 years-old (range: 3 mo to 81-years-old). Furthermore, four children were under 2-years-old, and 36 cases were adults 26-81 years-old. The most common indications for the treatment with vancomycin were endocarditis (*n* = 6), sepsis (*n* = 6), pneumonia (*n* = 5), and cellulitis (*n* = 2). These were followed by other various indications, such as prosthetic infection, hemodialysis, bone graft, acute pancreatitis, *etc*. The diagnosis of VIT mainly relied on the platelet count, with or without the Naranjo score[13]. The test results for the vancomycin-dependent antibodies were available for 19 patients, and all except three were positive. Among the 27 patients with available bleeding information, 21 patients exhibited bleeding signs. The treatments for these cases comprised of platelet transfusion, prednisone, dexamethasone, immunoglobulin, and daptomycin, and the discontinuation of vancomycin. For the six cases with endocarditis, VIT was diagnosed as probable by the Naranjo score. The information on bleeding signs was available for four cases, and three of these cases presented with bleeding signs. The presence of vancomycin-dependent antibodies was examined only in two patients, and positive results were obtained in one of them. After vancomycin discontinuation, VIT was generally resolved for all patients within 4-15 d. Despite clinical significance revealed by the present literature review, it must be clearly stated that this is only a narrative review, which possesses all the limitations of the selection of papers. Thus, a methodologically acceptable systematic review should be carried out when more data with high quality are available in order to draw a firm conclusion.

The present patient with infective endocarditis was diagnosed with VIT, which rapidly progressed. The early diagnosis of VIT was performed using the time-to-platelet count curve and Naranjo score. During treatment, the repeated platelet transfusions failed to increase the platelet levels. Subsequently, simply switching vancomycin to daptomycin returned the platelet count close to the baseline level.

The early diagnosis of VIT is quite difficult due to many suspected causes, such as severe infection, disseminated intravascular coagulation, heparin, and other medications. The correct diagnosis can be masked by the simultaneous administration of medications, which can cause drug-induced immune thrombocytopenia[14] or a complicating disease, such as primary idiopathic thrombocytopenic purpura or chronic hepatitis C[15]. Therefore, the early recognition of VIT was of key importance for the following treatment. According to previous studies[6], the investigators used the platelet count at different time points as the initial diagnosis of VIT, which can reveal a definite time-independent relationship with drug administration. All other causes of thrombocytopenia were excluded. Furthermore, the Naranjo score, which has been applied to help with the diagnosis of VIT[16-18], also indicated a probable correlation between thrombocytopenia and vancomycin. Noticeably, endocarditis represents the most common indication that is associated with VIT. The probable correlation between thrombocytopenia and vancomycin can be made through the Naranjo score for all cases, indicating that the Naranjo score is a useful tool to initially diagnose VIT in patients with endocarditis. A bleeding sign is also a useful clinical manifestation to which attention should be given in order to make a definite diagnosis, since most cases would present bleeding signs when VIT occurs. This is particularly true in patents with endocarditis, based on the analyzed data. However, the value of the detection of vancomycin-dependent antibodies in the diagnosis of VIT in patients with endocarditis remains to be elucidated due to the very limited data available.

The critical management after suspicions of VIT is to determine whether to continue or discontinue the vancomycin therapy. The seriousness of the bleeding and the dropping trend of the platelet count should be carefully considered and closely monitored when continuing the vancomycin therapy. However, once VIT is diagnosed, the vancomycin must be stopped, and the platelet transfusion should be taken into consideration as a supplemental treatment for some patients with various success rates, although there are still some transfusion-resistant patients[10,13,19,20]. If vancomycin is not stopped, the survival time of the transfused platelets would be obviously reduced, and the platelet transfusion will not always expectedly increase the platelet count of affected patients[3]. In any of these circumstances, platelet transfusion should be considered for severe thrombocytopenia with a platelet count of below 20 × 109/L and bleeding[19]. In addition to platelet transfusion, therapies with intravenous corticosteroids, intravenous immunoglobulins, rituximab, and plasma exchange have been shown to be beneficial in some cases after vancomycin discontinuation[3,21-23]. However, these medical approaches may not always be effective. In the present case, VIT was effectively resolved by platelet transfusion with the switching of vancomycin to daptomycin.

The mechanisms of VIT remains unclear. The formation of different drug-dependent platelet antibodies, including hapten-dependent, quinine-type, fiban-type and drug-specific antibodies, and other platelet destruction antibodies, are the widely documented mechanisms for VIT[11,21,24]. In contrast, naturally occurring antibodies may not contribute to VIT[25]. It has been postulated that vancomycin can bind to platelet glycoproteins and induce the generation of antibodies, which can attach to the drug-platelet complex, resulting in cell lysis[26]. In the present case, the platelet count gradually dropped after the administration of vancomycin (1000 mg per day) for 7 d. Although the vancomycin was changed to a low-dose (500 mg per day), the platelet count continued to drop. It was postulated that the persistent thrombocytopenia might be due to the anamnestic response for vancomycin re-exposure, and vancomycin-dependent antiplatelet antibodies were formed once vancomycin was re-used.

**CONCLUSION**

The present case highlights the importance of the accurate diagnosis of VIT in patients with endocarditis. The time-to-platelet count curve and Naranjo score are useful tools for the diagnosis of VIT. The platelet count cannot be normalized simply by platelet transfusion alone. Instead, the discontinuation of vancomycin or switching vancomycin to other antibiotics, such as daptomycin, is essential for effectively treating VIT. Due to the anamnestic response to vancomycin re-exposure and the formation of vancomycin-dependent antiplatelet antibodies, the re-administration of vancomycin should be avoided.

**REFERENCES**

1 **Patel N**, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP. A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. *J Antimicrob Chemother* 2012; **67**: 727-735 [PMID: 22174041 DOI: 10.1093/jac/dkr522]

2 **Rao N**, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. *Clin Infect Dis* 2004; **38**: 1058-1064 [PMID: 15095207 DOI: 10.1086/382356]

3 **van den Bemt PM**, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. *Drug Saf* 2004; **27**: 1243-1252 [PMID: 15588119 DOI: 10.2165/00002018-200427150-00007]

4 **Aster RH**, Bougie DW. Drug-induced immune thrombocytopenia. *N Engl J Med* 2007; **357**: 580-587 [PMID: 17687133 DOI: 10.1056/NEJMra066469]

5 **Aster RH**, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. *J Thromb Haemost* 2009; **7**: 911-918 [PMID: 19344362 DOI: 10.1111/j.1538-7836.2009.03360.x]

6 **Loo AS**, Gerzenshtein L, Ison MG. Antimicrobial drug-induced thrombocytopenia: a review of the literature. *Semin Thromb Hemost* 2012; **38**: 818-829 [PMID: 23081819 DOI: 10.1055/s-0032-1328882]

7 **Levine DP**. Vancomycin: understanding its past and preserving its future. *South Med J* 2008; **101**: 284-291 [PMID: 18364659 DOI: 10.1097/SMJ.0b013e3181647037]

8 **Rao N**, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. *Clin Orthop Relat Res* 2004: 67-71 [PMID: 15552139 DOI: 10.1097/01.blo.0000144860.11193.5e]

9 **Nasraway SA**, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. *Clin Infect Dis* 2003; **37**: 1609-1616 [PMID: 14689341 DOI: 10.1086/379327]

10 **Candemir B**, Aribuca A, Koca C, Ozcan OU, Gerede M, Kaya CT. An unusual case of vancomycin-related systemic reaction accompanied with severe thrombocytopenia mimicking pacemaker-related infective endocarditis: a case report and review of literature. *J Interv Card Electrophysiol* 2013; **38**: 143-145 [PMID: 23080329 DOI: 10.1007/s10840-012-9738-6]

11 **Shah RA**, Musthaq A, Khardori N. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. *J Med Case Rep* 2009; **3**: 7290 [PMID: 19830166 DOI: 10.4076/1752-1947-3-7290]

12 **Liu C**, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. *Clin Infect Dis* 2011; **52**: e18-e55 [PMID: 21208910 DOI: 10.1093/cid/ciq146]

13 **Lobo N**, Ejiofor K, Thurairaja R, Khan MS. Life-threatening haematuria caused by vancomycin-induced thrombocytopenia. *BMJ Case Rep* 2015; **2015** [PMID: 25716041 DOI: 10.1136/bcr-2014-208192]

14 **MacDougall KN**, Parylo S, Sokoloff A. A Case of Vancomycin-Induced Immune Thrombocytopenia. *Cureus* 2020; **12**: e7940 [PMID: 32499980 DOI: 10.7759/cureus.7940]

15 **Schueler SA**, Shet NS, Stienstra N, Chen DC. A Masked Case of Vancomycin-induced Immune Thrombocytopenia. *Am J Med Sci* 2016; **351**: 636 [PMID: 27238931 DOI: 10.1016/j.amjms.2016.03.005]

16 **Chen QY**, Wan J, Yang JH, Lin M, Chen Y. Vancomycin-induced severe thrombocytopenia in a young infant. *Rev Soc Bras Med Trop* 2018; **51**: 873-875 [PMID: 30517547 DOI: 10.1590/0037-8682-0150-2018]

17 **Danieletto CF**, Ferreira GZ, Farah GJ, Cuman RK. Vancomycin-induced thrombocytopenia: a rare adverse effect in a patient -submitted to bone graft in the jaw. *Spec Care Dentist* 2017; **37**: 38-42 [PMID: 27059302 DOI: 10.1111/scd.12182]

18 **Getz TM**, Packer CD. Rapid-Onset Vancomycin-Induced Thrombocytopenia With Reexposure. *Ann Pharmacother* 2019; **53**: 1259-1261 [PMID: 31353923 DOI: 10.1177/1060028019867433]

19 **Mohammadi M**, Jahangard-Rafsanjani Z, Sarayani A, Hadjibabaei M, Taghizadeh-Ghehi M. Vancomycin-Induced Thrombocytopenia: A Narrative Review. *Drug Saf* 2017; **40**: 49-59 [PMID: 27848200 DOI: 10.1007/s40264-016-0469-y]

20 **Kenney B**, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. *Platelets* 2008; **19**: 379-383 [PMID: 18791945 DOI: 10.1080/09537100802082280]

21 **O'Donnell E**, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. *Am J Hematol* 2007; **82**: 1122 [PMID: 17665503 DOI: 10.1002/ajh.20916]

22 **Ganly P**, Downing J, Stiven P, Frizelle F, Badami K. Clinical and serological diagnoses of a patient with vancomycin-induced thrombocytopenia. *Transfus Med* 2011; **21**: 137-139 [PMID: 21083776 DOI: 10.1111/j.1365-3148.2010.01052.x]

23 **Arnold DM**, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. *Transfus Med Rev* 2013; **27**: 137-145 [PMID: 23845922 DOI: 10.1016/j.tmrv.2013.05.005]

24 **Winteroll S,** Kerowgan M, Vahl CF, Leo A. Vancomycin-mediated drug-induced immune thrombocytopenia. *Transfus Med Hemother* 2004; **32**: 20-23 [DOI: 10.1159/000082126]

25 **Von Drygalski A**, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, Baker KR, Aster RH. Vancomycin-induced immune thrombocytopenia. *N Engl J Med* 2007; **356**: 904-910 [PMID: 17329697 DOI: 10.1056/NEJMoa065066]

26 **Rondina MT**, Walker A, Pendleton RC. Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. *Hosp Pract (1995)* 2010; **38**: 19-28 [PMID: 20469610]

27 **Ajit NE**, Devarashetty SP, Master S. Vancomycin Induced Thrombocytopenia - Protracted Course in a Hemodialysis Patient. *Case Rep Oncol* 2019; **12**: 749-754 [PMID: 31762746 DOI: 10.1159/000503418]

28 **Kalra K**, Mittal HG, Maria A. Vancomycin-induced thrombocytopenia in a newborn. *Drug Metab Pers Ther* 2016; **31**: 235-237 [PMID: 27849621 DOI: 10.1515/dmpt-2016-0021]

29 **Yamanouchi J**, Hato T, Shiraishi S, Takeuchi K, Yakushijin Y, Yasukawa M. Vancomycin-induced Immune Thrombocytopenia Proven by the Detection of Vancomycin-dependent Anti-platelet Antibody with Flow Cytometry. *Intern Med* 2016; **55**: 3035-3038 [PMID: 27746445 DOI: 10.2169/internalmedicine.55.6902]

30 **Ahmed Y,** Sartin C, Umer I. Vancomycin-induced severe asymptomatic immune thrombocytopenia: a rare cause. *Southwest Respir Crit Care Chronicles* 2015; **3**: 42-45 [DOI: 10.12746/swrccc.v3i9.159]

31 **Wetzel DR,** Njathi CW, Teleszm BJ, Stewartm TM, Smischney NJ. Thrombocytopenia of unusual etiology in the intensive care unit. *J Med Cases* 2013; **4**: 792-795 [DOI: 10.4021/jmc1555w]

32 **Ruggero MA**, Abdelghany O, Topal JE. Vancomycin-induced thrombocytopenia without isolation of a drug-dependent antibody. *Pharmacotherapy* 2012; **32**: e321-5 [PMID: 23065779 DOI: 10.1002/phar.1132]

33 **Rowland SP**, Rankin I, Sheth H. Vancomycin-induced thrombocytopaenia in a patient with severe pancreatitis. *BMJ Case Rep* 2013; **2013** [PMID: 24132444 DOI: 10.1136/bcr-2013-200830]

34 **Anand A**, Chauhan HK. Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient. *Platelets* 2011; **22**: 294-301 [PMID: 21309645 DOI: 10.3109/09537104.2010.549973]

35 **Lee JH,** Kim DS, Lee HS, Choi SI, Cho YG. A case of vancomycin induced thrombocytopenia. *Korean J Hematol* 2009; **44**: 294–297 [DOI: 10.5045/kjh.2009.44.4.294]

36 **Apiwattanakul N**, Wanitkun S, Chongtrakool P, Sirinavin S. A patient with penicillin-resistant viridans group streptococcal endocarditis and unusual reactions to vancomycin. *Southeast Asian J Trop Med Public Health* 2008; **39**: 1088-1091 [PMID: 19062700]

37 **Pauldine R**, Pustavoitau A. Case report: vancomycin-induced thrombocytopenia in a burn patient. *Eplasty* 2008; **8**: e39 [PMID: 18725952]

38 **Dilli D**, Oğuz SS, Dilmen U. A newborn with vancomycin-induced thrombocytopenia. *Pharmacology* 2008; **82**: 285-286 [PMID: 18931535 DOI: 10.1159/000163099]

39 **Bay A**, Oner AF, Dogan M, Caksen H. A child with vancomycin-induced thrombocytopenia. *J Emerg Med* 2006; **30**: 99-100 [PMID: 16434347 DOI: 10.1016/j.jemermed.2005.11.017]

40 **Peel RK,** Sykes A, Ashmore S, Turney JH, Woodrow G. A case of immune thrombocytopenic purpura from intraperitoneal vancomycin use. *Perit Dial Int* 2003; **23**: 506-508 [DOI: 10.1177/089686080302300520]

41 **Marraffa J**, Guharoy R, Duggan D, Rose F, Nazeer S. Vancomycin-induced thrombocytopenia: a case proven with rechallenge. *Pharmacotherapy* 2003; **23**: 1195-1198 [PMID: 14524652 DOI: 10.1592/phco.23.10.1195.32765]

42 **Rocha JL**, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. *Braz J Infect Dis* 2002; **6**: 196-200 [PMID: 12204187 DOI: 10.1590/s1413-86702002000400007]

43 **Shahar A**, Berner Y, Levi S. Fever, rash, and pancytopenia following vancomycin rechallenge in the presence of ceftazidime. *Ann Pharmacother* 2000; **34**: 263-264 [PMID: 10676837 DOI: 10.1345/aph.19051]

44 **Govindarajan R**, Baxter D, Wilson C, Zent C. Vancomycin-induced thrombocytopenia. *Am J Hematol* 1999; **62**: 122-123 [PMID: 10509053 DOI: 10.1002/(sici)1096-8652(199910)62:2<122::aid-ajh14>3.0.co;2-r]

45 **Kuruppu JC**, Le TP, Tuazon CU. Vancomycin-associated thrombocytopenia: case report and review of the literature. *Am J Hematol* 1999; **60**: 249-250 [PMID: 10072125 DOI: 10.1002/(sici)1096-8652(199903)60:3<249::aid-ajh20>3.0.co;2-h]

46 **Mizon P**, Kiefel V, Mannessier L, Mueller-Eckhardt C, Goudemand J. Thrombocytopenia induced by vancomycin-dependent platelet antibody. *Vox Sang* 1997; **73**: 49-51 [PMID: 9269071 DOI: 10.1046/j.1423-0410.1997.7310049.x]

47 **Zenon GJ**, Cadle RM, Hamill RJ. Vancomycin-induced thrombocytopenia. *Arch Intern Med* 1991; **151**: 995-996 [PMID: 2025149 DOI: 10.1001/archinte.1991.00400050133025]

48 **Christie DJ**, van Buren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. *Blood* 1990; **75**: 518-523 [PMID: 2295006 DOI: 10.1182/blood.V75.2.518.518]

49 **Carmichael A,** Al-Zahawi M. Drug points: pancytopenia associated with vancomycin. *Br Med J* 1986; **293**: 1103 [DOI: 10.1136/bmj.293.6554.1103-c]

**Footnotes**

**Informed consent statement:** An informed written consent was obtained from the patient for the publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** October 13, 2020

**First decision:** December 13, 2020

**Article in press:**

**Specialty type:** Pharmacology and pharmacy

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Momčilović S **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 Time-to-platelet count curve during hospitalization.** Vancomycin was initiated on day 2 and continued on day 43, as indicated by the downward arrows. Platelet transfusion was given on day 11, 17, 33, and 43, as indicated by the upward arrows.

**Table 1 Summary of case reports of vancomycin-induced thrombocytopenia**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author (publication year)** | **Age (yr)** | **Gender** | **Indication** | **Platelet count**  **(109/L)1** | **Naranjo Score** | **Treatment** | **Time for resolution (d)2** | **Vancomycin-dependent antibodies** | **Bleeding sign** |
| Present case | 26 | M | Endocarditis | 27 | Probable | Platelet transfusion and daptomycin | 12 | NA | + |
| MacDougall *et al*[14] (2020) | 81 | M | Prosthetic infection | 2 | NA | Prednisone, immunoglobulin, and daptomycin | 10 | + | - |
| Ajit *et al*[27] (2019) | 61 | M | Hemodialysis | < 10 | NA | Prednisone, immunoglobulin, eltrombopag and plasma exchange | 15 | + | + |
| Getz *et al*[18] (2019) | 71 | M | Transverse myelitis | 8.6 | Definite | Dexamethasone and immunoglobulin | 8 | + | + |
| Chen *et al*[16] (2018) | 0 | F | Purulent meningitis | 8 | Probable | Methylprednisolone | 4 | + | + |
| [Danieletto](about:blank) *et al*[17] (2017) | 57 | F | Bone graft | 9 | Probable | Tigecycline | 7 | - | - |
| Kalra *et al*[28] (2016) | 0.7 | M | Sepsis | 30 | NA | Platelet transfusion | 3 | NA | - |
| [Schueler](about:blank) *et al*[15] (2016) | 55 | M | Purpura | 1 | NA | Prednisone and immunoglobulin | 3 | NA | + |
| [Yamanouchi](about:blank) *et al*[29] (2016) | 72 | F | Sepsis | 2 | NA | Steroid therapy and carbapenem | 7 | + | + |
| Lobo *et al*[13](2015) | 67 | M | Pneumonia | 2 | Probable | Platelet transfusion， methylprednisolone and immunoglobulin | 3 | + | + |
| Ahmed *et al*[30] (2015) | 63 | M | Diabetic foot | 2 | Probable | Daptomycin | 10 | + | - |
| Candemir *et al*[10] (2013) | 54 | F | Hematoma | 42 | Probable | Platelet transfusion and daptomycin | 4 | NA | NA |
| Wetzel *et al*[31] (2013) | 64 | F | Sepsis | 7 | Probable | Prednisone and immunoglobulin | 8 | NA | + |
| Ruggero *et al*[32] (2012) | 41 | M | Pneumonia | 15 | Definite | Daptomycin | 5 | NA | + |
| Arnold *et al*[23] (2013) | 66 | F | Endocarditis | 4 | Probable | Platelet transfusion and immunoglobulin | 5 | + | + |
| Rowland *et al*[33] (2013) | 51 | M | Acute pancreatitis | 9 | Probable | Only vancomycin discontinuation | 5 | NA | + |
| Anand *et al*[34] (2011) | 54 | M | Cellulitis | 1 | Possible | Corticosteroids and daptomycin | 2 | + | + |
| Ganly *et al*[22] (2011) | 67 | M | Sepsis | 2 | NA | Platelet transfusion and immunoglobulin | 8 | NA | + |
| Shah *et al*[11] (2009) | 60 | M | Shoulder infection | 9 | Possible | Platelet transfusion | 3 | + | + |
| Lee *et al*[35] (2009) | 76 | M | Diabetic foot | < 15 | Possible | Platelet transfusion and teicoplanin. | 5 | + | - |
| Apiwattanakul *et al*[36] (2008) | 16 | F | Endocarditis | 123 | Possible | Prednisone and cefotaxime | 5 | NA | - |
| Kenney *et al*[20] (2008) | 61 | M | Gangrene and bacteremia | 3 | Probable | Platelet transfusion and immunoglobulin | 4 | + | + |
| Pauldine *et al*[37] (2008) | 60 | M | Pneumonia | 10 | Possible | Platelet transfusion | 12 | + | + |
| Dilli *et al*[38] (2008) | 0.6 | M | Neonatal respiratory distress | 41 | NA | Only vancomycin discontinuation | 3 | - | NA |
| O’Donnell *et al*[21] (2007) | 56 | F | Prosthetic infection | 2 | Possible | Immunoglobulin | 7 | + | + |
| Bay *et al*[39] (2006) | 2 | M | Pneumonia | 11 | NA | Only vancomycin discontinuation | 4 | NA | NA |
| Winteroll *et al*[24] (2004) | 72 | M | Sepsis | 3 | Probable | Platelet transfusion | 10 | + | + |
| Peel *et al*[40] (2003) | 45 | M | Peritonitis | 5 | Probable | Platelet transfusion and prednisone | 4 | NA | + |
| Marraffa *et al*[41] (2003) | 50 | M | Endocarditis | 10 | Probable | Clindamycin and methylprednisolone | 5 | NA | + |
| Rocha *et al*[42] (2002) | 38 | F | Prosthetic infection | 68 | Possible | Only vancomycin discontinuation | 4 | NA | NA |
| Shahar *et al*[43] (2000) | 43 | F | Surgery-site infection | 118 | Probable | Only vancomycin discontinuation | 3 | NA | NA |
| Govindarajan *et al*[44] (1999) | 72 | M | Epidural abscess | 13 | Probable | Trimethoprim/sulfmethoxazole | 10 | NA | NA |
| Kuruppu *et al*[45] (1999) | 72 | F | Endocarditis | 14 | Possible | Only vancomycin discontinuation | 5 | - | NA |
| Mizon *et al*[46] (1997) | 71 | F | Sepsis | < 10 | Probable | Antibiotics withdrawn | 4 | + | + |
| Zenon *et al*[47] (1991) | 54 | M | Cellulitis | 17 | Probable | Antibiotics withdrawn | 7 | NA | NA |
| Christie *et al*[48] (1990) | 73 | F | Pneumonia | 14 | Probable | Platelet transfusion | 2 | + | NA |
| Christie *et al*[48] (1990) | 31 | M | Fever | < 10 | Possible | Platelet transfusion | 11 (not continued) | + | NA |
| Carmichael *et al*[49] (1986) | 42 | F | Endocarditis | 82 | Possible | NA | 9 | NA | NA |

1The lowest value during the vancomycin treatment; 2The time from vancomycin discontinuation to the resolution of vancomycin-induced thrombocytopenia. +: A positive result; -: A negative result. F: Female; M: Male; NA: Not available or not tested.